세계의 핵산 증폭 검사(NAAT) 시장 : 기술별, 용도별, 최종사용자별 - 기회 분석 및 산업 예측(2023-2032년)

Nucleic Acid Amplification Testing Market By Technology (Polymerase Chain Reaction Tests, Isothermal Nucleic Acid Amplification Technology Tests), By Application, By End-user : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,093,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,560,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계 핵산 증폭 검사(NAAT) 시장 규모는 2022년 46억 달러로 2023-2032년 CAGR 6.6%를 기록하며 2032년 91억 달러에 달할 것으로 예상됩니다. NAAT라고도 불리는 핵산 증폭 검사는 바이러스 감염을 확인하는 데 사용되는 실험실 검사의 일종입니다.

이러한 검사는 검사 샘플에서 소량의 DNA 또는 RNA를 검출하는 데 사용되기 때문에 혈액 또는 소변 샘플에서 박테리아 또는 바이러스를 검출하는 데 사용됩니다. 핵산 증폭 검사의 가장 큰 장점은 소량의 검사 시료에서 원하는 물질을 검출할 수 있다는 것입니다. 이 방법은 중합효소연쇄반응(PCR), 사슬치환분석(SDA), 전사매개분석(TMA)을 사용하여 DNA 또는 RNA 서열을 증폭합니다.

핵산 증폭 검사(NAAT)는 소량의 DNA 또는 RNA를 채취한 후 이를 몇 배로 증식시켜 배양할 필요 없이 시료 내 미량의 박테리아를 확인합니다. 이 방법은 희귀하거나 기존 기술로는 배양 및 식별이 어려운 박테리아에 특히 유용합니다. 핵산 증폭 검사는 B형 간염, C형 간염, 거대 세포 바이러스, 인간 T세포 림프종 바이러스, 호흡기 바이러스 감염, 성병과 같은 감염성 질환의 진단을 위한 정성 및 정량적 파라미터를 검출하는 데 사용됩니다. 이러한 감염성 질환이 증가함에 따라 핵산 증폭 검사에 대한 수요가 증가하여 전 세계적으로 시장 성장을 촉진하고 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
    • 첨단 진단 기술에 대한 수요 급증
    • 감염증 증가
    • 암 환자 급증
  • 성장 억제요인
    • 첨단 진단 기술에 관한 인식 부족
    • 첨단 진단 검사에 숙련된 인재의 부족
  • 기회
    • POC(Point of Care) 검사에 대한 인식과 수요 증가

제4장 핵산 증폭 검사(NAAT) 시장 : 기술별

• 개요
• 중합효소 연쇄 반응(PCR) 검사
• 등온 핵산 증폭 기술(INAAT) 검사

제5장 핵산 증폭 검사(NAAT) 시장 : 용도별

• 개요
• 감염증 검사
• 종양학 검사
• 기타

제6장 핵산 증폭 검사(NAAT) 시장 : 최종사용자별

• 개요
• 병원내 검사실
• 중앙 검사실, 표준 검사실, 독립형 검사실
• 기타

제7장 핵산 증폭 검사(NAAT) 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10개사 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제9장 기업 개요

• Hologic, Inc.
• New England Biolabs.
• Grifols, S.A.
• BioMerieux SA
• Illumina Inc.
• Abbott Laboratories
• Perkin Elmer Inc
• F. Hoffmann-La Roche Ltd.
• Eiken Chemical Co., Ltd.
• Siemens AG

ksm

영문 목차

영문목차

The nucleic acid amplification testing market was valued at $4.6 billion in 2022 and is estimated to reach $9.1 billion by 2032, exhibiting a CAGR of 6.6% from 2023 to 2032. Nucleic acid amplification testing, also known as NAAT, is a type of laboratory testing used for identification of viral infections. These tests are used for the detection of small amounts of DNA or RNA in the test sample and thus, are used for detection of bacteria or viruses in the blood or urine sample. The material of interest be detected in a small amount of test samples which proves to be the major advantage of nucleic acid amplification testing. The method involves amplification of DNA or RNA sequences using a polymerase chain reaction (PCR), strand displacement assay (SDA), or transcription-mediated assay (TMA).

Nucleic acid amplification testing (NAAT) identifies minute quantities of an organism in a specimen without the requirement for culture by taking small quantities of DNA or RNA and multiplying it many times. These methods are especially helpful for organisms that are scarce or difficult to cultivate or identify using conventional techniques. Nucleic acid amplification testing is used for detection of both qualitative and quantitative parameters for diagnosis of infections such as hepatitis B, hepatitis C, cytomegalovirus, human T-cell lymphotropic virus, respiratory virus infections, and sexually transmitted infections and others. As the incidences of these infections are on the rise, there is an increasing demand for the nucleic acid amplification testing which boosts market growth globally.

In addition, surge in demand for rapid diagnostic testing and increase in R&D activities to develop advance diagnostic techniques are the major factors driving the growth of the nucleic acid amplification testing market. Key players in the market invest on a large scale to develop new diagnostic tests that are highly precise and require less time as compared to traditional methods.

However, lack of skilled laboratory personnels and limited awareness among the people in low- and middle-income countries are anticipated to hamper the market growth. As people in the underdeveloped countries have limited awareness, the diseases and infections go undiagnosed, thereby acting as a restraint to market growth.

On the other hand, a rise in investment by the key players is anticipated to boost the market growth in the coming years. The key players in the market are investing on a large scale to innovate and develop new diagnostic procedures that are efficient and require less time as compared to the traditional methods. As newer tests are developed, they are expected to boost market growth during the forecast period.

The nucleic acid amplification testing market is segmented on the basis of technology, application, end user, and region. By technology, the market is segmented into polymerase chain reaction (PCR) tests, and isothermal nucleic acid amplification technology (INAAT) test. The INAAT segment is further divided into loop mediated isothermal amplification (LAMP), transcription mediated amplification (TMA), nucleic acid sequence based amplification (NASBA), helicase dependent amplification (HDA), rolling circle amplification (RCA) and others. On the basis of application, the market is categorized into infectious disease testing, oncology testing and other. On the basis of end user, the market is divided into hospitals-based laboratories, central, reference and standalone laboratories, and others.

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Hologic, Inc., Grifols, S.A., BioMerieux SA, Illumina Inc., Abbott Laboratories, Perkin Elmer Inc, F. Hoffmann-La Roche Ltd., Siemens AG, Eiken Chemical Co., Ltd. and New England Biolabs.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid amplification testing market analysis from 2022 to 2032 to identify the prevailing nucleic acid amplification testing market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the nucleic acid amplification testing market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global nucleic acid amplification testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By End-user

• Hospital Based Laboratories
• Central, Reference and Standalone Laboratories
• Others

By Technology

• Polymerase Chain Reaction (PCR) Tests
• Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
  • Type
  • Loop mediated isothermal amplification (LAMP)
  • Transcription mediated amplification (TMA)
  • Nucleic acid sequence based amplification (NASBA)
  • Helicase dependent amplification (HDA)
  • Rolling circle amplification (RCA)
  • Others

By Application

• Infectious Disease Testing
• Oncology Testing
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Grifols, S.A.
• Hologic, Inc.
• Illumina Inc.
• F. Hoffmann-La Roche Ltd.
• Eiken Chemical Co., Ltd.
• BioMerieux SA
• Abbott Laboratories
• Perkin Elmer Inc
• Siemens AG
• New England Biolabs.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. High bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Surge in demand for advanced diagnostic techniques
    • 3.4.1.2. Rise in incidences of infectious diseases
    • 3.4.1.3. Surge in prevalence of cancer cases
  • 3.4.2. Restraints
    • 3.4.2.1. Lack of awareness regarding advanced diagnostic techniques
    • 3.4.2.2. Lack of skilled personnel for advanced diagnostic testing
  • 3.4.3. Opportunities
    • 3.4.3.1. Rising awareness and demand for point of care testing

CHAPTER 4: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Polymerase Chain Reaction (PCR) Tests
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
  • 4.3.4. Isothermal Nucleic Acid Amplification Technology (INAAT) Tests Nucleic Acid Amplification Testing Market by Type

CHAPTER 5: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Infectious Disease Testing
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Oncology Testing
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Based Laboratories
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Central, Reference and Standalone Laboratories
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Technology
  • 7.2.3. Market size and forecast, by Application
  • 7.2.4. Market size and forecast, by End-user
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Technology
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by End-user
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Technology
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by End-user
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Technology
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by End-user
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Technology
  • 7.3.3. Market size and forecast, by Application
  • 7.3.4. Market size and forecast, by End-user
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Technology
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by End-user
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Technology
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by End-user
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Technology
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by End-user
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Technology
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by End-user
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Technology
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by End-user
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Technology
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by End-user
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Technology
  • 7.4.3. Market size and forecast, by Application
  • 7.4.4. Market size and forecast, by End-user
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Technology
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by End-user
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Technology
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by End-user
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Technology
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by End-user
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Technology
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by End-user
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Technology
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by End-user
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Technology
    • 7.4.5.6.2. Market size and forecast, by Application
    • 7.4.5.6.3. Market size and forecast, by End-user
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Technology
  • 7.5.3. Market size and forecast, by Application
  • 7.5.4. Market size and forecast, by End-user
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Technology
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by End-user
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Technology
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by End-user
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Technology
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by End-user
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Technology
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by End-user

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Hologic, Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. New England Biolabs.
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
• 9.3. Grifols, S.A.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. BioMerieux SA
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Illumina Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Abbott Laboratories
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Perkin Elmer Inc
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. F. Hoffmann-La Roche Ltd.
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Eiken Chemical Co., Ltd.
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Siemens AG
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료